Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Noxopharm, New Corporate Presentation (ASX:NOX)

- Singapore, Hong Kong roadshow - July 26-28, 2017 Sydney, 25 July 2017: Noxopharm Limited (ASX: NOX) provides its latest Corporate Presentation ahead of a roadshow (26-28 ) in Asia. To vie...read more

Noxopharm Provides Update on NOX66 Clinical Trial Program (ASX:NOX)

Shortened clinical development program marketing approval and revenue stream targeted for 2021 prostate cancer likely indication for initial marketing approval. 6 July 2017, Sydney: The Co...read more

Noxopharm Announces Idronoxil Data Provides Hope to Treat Secondary Brain Cancers (ASX:NOX)

- Secondary brain cancer major cause of death in patients with breast cancer, lung cancer and melanoma - Secondary brain cancer at least 3-times incidence of primary brain cancer - Limited treat...read more

Noxopharm Announces NOX66 Confirmed Non-Toxic - Trial Cleared for Full Enrolment (ASX:NOX)

Scheduled checkpoint review of safety clears NOX66 monotherapy First group of patients complete Phase 1a arm Phase 1b combination treatment now underway Full recruitment anticipated by late-Jul...read more

Noxopharm announces release of Corporate Presentation (ASX:NOX)

Highlights 7 x NOX66 clinical studies in place by end - 2017 on-schedule for NOX66 efficacy data by end - 2017 timetable has registration studies commencing 2018 To ...read more

Noxopharm Announces St Vincent’s Hospital Sydney Cancer Study to Commence with NOX66 + Radiotherapy (ASX:NOX)

- Combination of NOX66 + pioneering form of radiotherapy - Late-stage prostate cancer patients - Safety and efficacy study 29 May, Sydney: Noxopharm (ASX:NOX) today announces the involvement ...read more

Noxopharm Announces Strategic Commitment Made to Treatment of Rare Cancers (ASX:NOX)

- Population of cancer patients with limited treatment options - Conversion of compassionate use scheme into formal study - Additional to existing clinical program - Designed to provide data ...read more

Noxopharm, The Australian Financial Review - Innovations in Cancer Research (ASX:NOX)

Cell focus offers new hope An Australian biotechnology company says it has come up with an innovative drug that has the potential to transform the treatment of people with cancer – and make a...read more

Noxopharm (ASX:NOX) Mid-Year Investor Briefings (ASX:NOX)

Noxopharm CEO , Dr Graham Kelly, and Director of Clinical Development and Medical Affairs, Mr Ian Minns, will present updates on Noxopharm's (ASX:NOX) NOX66 clinical programme and onocology a...read more

Noxopharm Releases Market Guidance for Next Six Months (ASX:NOX)

Patients currently receiving NOX66 and chemotherapy Six additional clinical trials to start within next 6 months Program of planned release in 2017 of data as it becomes available. Sydney,...read more

Noxopharm Limited, Appendix 4C - March 2017 Quarter (ASX:NOX)

Treatment of patients with NOX66 commences Clinical-stage status achieved within 7 months of IPO Clinical strategy designed to deliver proof-of-concept data by end of 2017 ‘Smarter&...read more

Noxopharm Announces FNN Interview with CEO Explaining Idronoxil-C Discovery (ASX:NOX)

Noxopharm Limited ( ASX:NOX) provides shareholders with a video interview with CEO Dr Graham Kelly explaining the discovery of idronoxil-C. To view the interview, please visit the link below: ww...read more

Noxopharm Announces Patent Application Filed on ‘Smart’ - Idronoxil (ASX:NOX)

PCT patent lodged ‘Smarter’ form of idronoxil Opportunity for range of new anti-cancer products. Sydney, 10 April 2017: Following an announcement on 27 March 2017 about receiving F...read more

Noxopharm Announces Federal Grant Received for Collaboration with Monash University (ASX:NOX)

Identification of advanced form of idronoxil Study in support of marketing application for NOX66 Dosage form specific for urogenital cancers in women Sydney, 27 March 2017: A contract rese...read more

Noxopharm Announces UNSW Combine on Stroke Project (ASX:NOX)

- Noxopharm drug identified as potential brain/spinal cord injury preventative - First-in-class drug to hasten rehabilitation from brain and spinal cord injury - Made possible because of NOX66 d...read more

Viewing: 136 - 150 of 169 Previous | Next